MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance
Jordy C.G. van der Zwet(Princess Máxima Center), Jules P.P. Meijerink(Erasmus MC - Sophia Children’s Hospital), Adolfo A. Ferrando(Regeneron (United States)), Josef Vormoor(University Medical Center Utrecht), Zhongli Chen(Princess Máxima Center), Rob Pieters(Princess Máxima Center), Willem K. Smits(Princess Máxima Center), Jessica G. C. A. M. Buijs-Gladdines(Princess Máxima Center), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Jan Cools(KU Leuven), Koichi Oshima(Columbia University Irving Medical Center), Jelle Dylus(Center for Translational Molecular Medicine), Donna O. Debets(Utrecht University), Guido J.R. Zaman(GlaxoSmithKline (Netherlands)), Valentina Cordo’(Princess Máxima Center), Beat Bornhäuser(University Children's Hospital Zurich), Britta Vormoor(Princess Máxima Center), Maarten Altelaar(Utrecht University)
Cited by 48
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
|Cancer Cell|2002|1.1k
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k